Hello, I am Dr. Hidenori Shimada of Grand Green Osaka Umekita Clinic in Osaka, Japan.
If you are considering NK cell therapy while living abroad or visiting Japan, the first consultation is where most of your questions can begin to be answered. A little preparation helps you use that time well. This article explains what international patients may want to gather and ask before meeting a doctor at Grand Green Osaka Umekita Clinic in Osaka, Japan.
The short answer: bring your records and your questions
NK cell therapy is a cancer immune cell therapy in which your own natural killer cells are obtained from a standard blood draw, activated and expanded at a specialized facility, and then returned by intravenous infusion. It is not a replacement for standard cancer treatment, and whether it is a reasonable option for you can only be judged by a physician after reviewing your situation. The most useful preparation is therefore to organize your medical history clearly and to write down what you want to understand, so the consultation can focus on your own circumstances rather than on general explanations.
What this therapy is, in plain language
NK cells are a type of lymphocyte that belongs to the innate immune system. They circulate in the blood and are known for recognizing abnormal cells, including cancer cells and virus-infected cells, without needing instructions from other immune cells. Their activity is reported to decline with age, stress and the effects of cancer itself. In NK cell therapy, the aim is to return a larger number of more active NK cells to the body to support your own immune response.
Because the cells come from you, the risk of rejection is considered low, and temporary reactions such as fever or fatigue have been described. Even so, every treatment carries uncertainty, and research on cell-based immunotherapies for cancer is still evolving. Public literature, including studies indexed in PubMed, describes a range of findings, and no single study should be read as a promise about what will happen to an individual patient.
Medical records worth gathering beforehand
Doctors can give more meaningful guidance when they can see the full picture of your diagnosis and treatment so far. If you can, collect the following and, where possible, have them available in English or with a translation.
- A referral letter or treatment summary from your current oncologist, including your diagnosis, stage and treatment history.
- Recent blood test results and imaging reports.
- Pathology reports and any genetic or biomarker test results.
- A list of current medications, supplements and known allergies.
- Details of your current and planned standard treatments, such as surgery, chemotherapy or radiation therapy, with dates.
Sharing information about your standard treatment matters because NK cell therapy is generally discussed as something that can be considered alongside surgery, chemotherapy or radiation therapy, not instead of them. The clinic can also coordinate with the medical institution providing your standard care when appropriate, and having contact details for your treating team makes that easier.
Questions to ask the doctor
It is easy to forget important points during a consultation, especially in a second language. Writing questions down in advance helps. Consider asking the following.
- Based on my records, is this therapy something that may be considered for my situation, and what are its limits?
- How would it fit with my current or planned standard treatment?
- What are the possible side effects and risks, and how are they monitored?
- How many visits and how much time in Japan would be involved, from blood draw to infusion?
- What is the full cost, and what is and is not included?
- What follow-up is available once I return home, and how can my local doctor be kept informed?
Do not hesitate to ask the doctor to repeat or clarify anything. A good consultation should leave you with a realistic understanding of both the possible benefits and the uncertainties, and you are free to take time to decide.
Understanding how treatment is provided in Japan
In Japan, NK cell therapy is offered as a self-pay treatment, which means it is not covered by public health insurance. It is provided under the country’s regenerative medicine law, which requires a provision plan to be reviewed by a certified committee and submitted to the Ministry of Health, Labour and Welfare, and requires cells to be processed at facilities that meet the law’s standards. For you as a patient, this means it is reasonable to ask how the clinic follows this framework and how your informed consent will be obtained.
Costs, risks, side effects and suitability are all matters that a physician needs to confirm during an examination. Fees in particular should be checked on the clinic’s fee page or directly with the staff, and you should confirm what is included before agreeing to any plan.
Practical points for patients coming from overseas
Grand Green Osaka Umekita Clinic is located in Umeda, a central and well-connected area of Osaka. The clinic provides a dedicated information page for international patients, with multilingual guidance and contact options, so you can ask logistical questions before you travel. It can help to ask in advance whether interpretation support is available, how appointments are scheduled, and how long you should plan to stay.
If you are traveling for treatment, also check practical matters such as passport and visa requirements, travel insurance, and how you will manage ongoing care at home. Discuss your travel plans with your current doctor, particularly if you are in the middle of chemotherapy or radiation therapy, because timing can matter.
Summary
A first consultation about NK cell therapy works best when you arrive with organized medical records, a written list of questions, and a clear understanding that the therapy is a self-pay option provided under Japanese regenerative medicine rules, to be considered alongside standard care. Whether it suits you, what it may cost, and what risks apply must be confirmed by a doctor after an examination. If you would like to learn more, you can read the clinic’s multilingual NK cell therapy information and contact Grand Green Osaka Umekita Clinic in Osaka to arrange a consultation.
- Gather your recordsDiagnosis and treatment history
- Write your questionsRisks, visits and follow-up
- Self-pay treatmentConfirm fees with staff
- Doctor decidesSuitability needs an exam
This diagram is a conceptual summary of the article content
References
- PubMed: Targeting triple-negative breast cancer using cord-blood CD34⁺ HSPC-derived mesothelin-specific CAR-NKT cells with potent antitumor activity. (2025)
- PubMed: Long-term survival after local immunotherapy for malignant gliomas: a retrospective study with 20 years follow-up. (2024)
- PubMed: Generating allogeneic CAR-NKT cells for off-the-shelf cancer immunotherapy with genetically engineered HSP cells and feeder-free differentiation culture. (2025)
- PubMed: Autologous adoptive immune-cell therapy elicited a durable response with enhanced immune reaction signatures in patients with recurrent glioblastoma: An open label, phase I/IIa trial. (2021)
- PubMed: A phase I clinical trial to evaluate the tolerability and safety of an allogeneic iPSC-derived iNKT cell and α-GalCer-pulsed autologous DC combination therapy for patients with recurrent and advanced head and neck cancer: A study protocol. (2026)
- PMC: Adoptive immunotherapy against ovarian cancer. (2016)
- PMC: Patients' NK cell stimulation with activated plasmacytoid dendritic cells increases dinutuximab-induced neuroblastoma killing. (2020)
- PMC: Preclinical evaluation and first-in-dog clinical trials of PBMC-expanded natural killer cells for adoptive immunotherapy in dogs with cancer. (2024)
- MHLW (Japan): Regenerative Medicine — Ministry of Health, Labour and Welfare, Japan
Supervising Physician
Director, Medical Corporation Shimada Clinic
Head of Clinical Practice, Grand Green Osaka Umekita Clinic
Hidenori Shimada
Graduated from the University of Tokushima Faculty of Medicine in 2005. After his initial residency, he obtained U.S. medical certification (ECFMG) and trained as a sub-intern in general surgery at the University of Washington. After completing the doctoral program at Kyoto University Graduate School of Medicine and working as a researcher at the Center for iPS Cell Research and Application (CiRA), Kyoto University, he founded Shimada Clinic in 2013. At Grand Green Osaka Umekita Clinic (https://umekitaclinic.org), he is engaged in a wide range of care, from internal medicine and pediatrics to cell therapy and aesthetic medicine.
* The physician supervision of this article covers its academic content only and does not constitute a recommendation of any specific treatment or product.